Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease
Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…Alpha-synuclein aggregates of cardiac sympathetic nerves in synucleinopathies and in neurologically unimpaired subjects. Correlation with sympathetic denervation
Objective: To study the cardiac sympathetic innervation and its relationship with the incidence of alpha-synuclein deposits in heart tissue of synucleinopathies and asymptomatic control patients.…Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein
Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…Toward a new biomarker on Parkinson’s disease: Study of alpha synuclein on upper enteric system by endoscopy
Objective: The aim of our study was to investigate the alpha synuclein deposition at the enteric nerve system on patient with Parkinson's disease and provide…Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker
Objective: We aimed to investigate the utility of alpha-synuclein (α-SYN) immunoreactivity from gastric and colonic mucosal tissues obtained by routine endoscopy to detect Parkinson's disease…
- « Previous Page
- 1
- …
- 8
- 9
- 10